Stockscreener 앱 받기
1.36
23.49%
-0.43
전일 마감가:
$1.79
열려 있는:
$1.34
하루 거래량:
415.60K
Relative Volume:
2.16
시가총액:
$24.21M
수익:
$128.60K
순이익/손실:
$-4.60M
주가수익비율:
-2.1587
EPS:
-0.63
순현금흐름:
$-3.74M
1주 성능:
-24.75%
1개월 성능:
-18.96%
6개월 성능:
-51.95%
1년 성능:
-4.56%
1일 변동 폭
$1.27
$1.4295
1주일 범위
$1.27
$1.92
52주 변동 폭
$0.53
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
명칭
Nexalin Technology Inc
전화
(832) 260-0222
주소
1776 YORKTOWN, HOUSTON
NXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
1.363 | 24.21M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
132.26 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.60 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.01 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.49 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.41 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Nexalin Technology Inc 주식(NXL)의 최신 뉴스
Nexalin Prices 3.85 Mln Public Offering At $1.30/shr; Stock Plunges In Pre-market - Nasdaq
Nexalin Technology slides after pricing $5M stock offering - MSN
Nexalin Technology sets public offering at $1.30 per share - Investing.com
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock - GlobeNewswire
Nexalin Technology Prices $5 Million Public Offering - marketscreener.com
SEC Form 424B5 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology, Inc. (NASDAQ:NXL) Shares Acquired by Geode Capital Management LLC - Defense World
SEC Form 424B4 filed by Nexalin Technology Inc. - Quantisnow
Nexalin Technology (NXL) Seeks FDA Feedback for Gen-2 SYNC Syste - GuruFocus
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design - marketscreener.com
Nexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive Disorders - Nasdaq
Nexalin Technology Initiates FDA Q-Submission Process for - GlobeNewswire
FDA Fast-Tracks Nexalin Gen-2 SYNC Review for Alzheimer's Treatment | NXL Stock News - Stock Titan
Nexalin Technology (NASDAQ:NXL) Shares Down 0.5% – Time to Sell? - Defense World
International Milestone for Anxiety-Insomnia Neurostim Company - Sleep Review
Nexalin Technology files $50M common stock offering - MSN
Nexalin Technology (NXL) Gains Approval for Clinical Trial in Br - GuruFocus
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia - marketscreener.com
Nexalin's Neurostimulation Device Begins Phase II Trial for Anxiety and Insomnia Treatment in Brazil - Stock Titan
Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings - marketscreener.com
Nexalin Technology (NXL) Launches Advanced Virtual Clinic for Mi - GuruFocus
Nexalin Technology Announces Launch of Virtual Clinic to Enhance Clinical Research and Patient Care for Mental Health Disorders - Nasdaq
Nexalin Technology Announces Completion of Phases One - GlobeNewswire
Advanced AI Virtual Clinic Powers Groundbreaking Military PTSD Study: Nexalin's New Digital Health Platform - Stock Titan
Nexalin Technology, Inc. Supports Health Tech Investment Act to Enhance Medicare Reimbursement for AI-Enabled Medical Devices - Nasdaq
Nexalin Technology Expresses Strong Support for Health Tech - GlobeNewswire
Medicare May Cover AI Mental Health Devices as Nexalin Backs New Bill | NXL Stock News - Stock Titan
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices - TradingView
Nexalin Technology appoints new accounting firm By Investing.com - Investing.com Canada
Nexalin Technology appoints new accounting firm - Investing.com
Nexalin secures patent on brain stimulation method for substance use disorders - Yahoo
Nexalin Secures Patent for Intracranial Stimulation Technology - marketscreener.com
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - The Manila Times
Nexalin Technology Secures USPTO Patent for Deep - GlobeNewswire
Game-Changing Patent: Nexalin's Brain Stimulation Tech Takes On $35B Addiction Treatment Market - Stock Titan
Nexalin begins clinical trial for brain stimulation therapy By Investing.com - Investing.com South Africa
Nexalin begins clinical trial for brain stimulation therapy - Investing.com
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - The Manila Times
Revolutionary Brain Treatment: Nexalin Launches PTSD Trial at UCSD with AI-Powered Home Therapy - Stock Titan
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3 - GlobeNewswire
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 - The Manila Times
Revolutionary Brain Tech Targets $537B Market: Nexalin CEO Reveals Growth Strategy - Stock Titan
Nexalin Technology (NASDAQ:NXL) Upgraded at Maxim Group - The AM Reporter
Nexalin Technology (NASDAQ:NXL) Upgraded to “Buy” at Maxim Group - Defense World
Maxim Group Upgrades Nexalin Technology (NXL) - Nasdaq
Nexalin Technology, Inc. SEC 10-K Report - TradingView
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat
Nexalin Technology’s Senior VP Makes a Bold Stock Purchase - TipRanks
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock - Investing.com India
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock By Investing.com - Investing.com UK
Nexalin Technology Inc (NXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nexalin Technology Inc 주식 (NXL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
3.10 |
1,000 |
3,100 |
155,793 |
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
2.98 |
1,000 |
2,980 |
154,793 |
| Owens David | Chief Medical Officer |
Jan 28 '25 |
Buy |
2.70 |
1,500 |
4,050 |
153,793 |
| Owens David | Chief Medical Officer |
Jan 13 '25 |
Buy |
2.50 |
2,000 |
5,000 |
151,293 |
| Owens David | Chief Medical Officer |
Jan 23 '25 |
Buy |
2.70 |
1,000 |
2,700 |
152,293 |
| Owens David | Chief Medical Officer |
Oct 28 '24 |
Buy |
2.19 |
500 |
1,095 |
148,293 |
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
10.06%
0.20%
자본화:
|
볼륨(24시간):